Insulet (PODD) Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary
Event summary combining transcript, slides, and related documents.
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum summary
24 Sep, 2026Business performance and market opportunity
Achieved strong Q2 results with 23% organic growth, 20% U.S. Omnipod growth, 33% international Omnipod growth, and 140 basis points of operating margin expansion.
Markets for automated insulin delivery (AID) remain large and under-penetrated, with only 5% of insulin-intensive type 2 diabetes patients in the U.S. using AID.
International business grew over 30% YoY, with 75% of the OUS DASH base converted to Omnipod 5 and new launches in Spain, Germany, and Canada.
High retention rates after 90 days for both type 1 and type 2 customers support a durable business model.
Type 2 IIT penetration is targeted to reach 10%-15% by 2028, with potential to go significantly higher, inspired by CGM adoption rates.
Strategic initiatives and corrective actions
Four key actions to improve type 2 retention: revamping the sampling program, adjusting field incentives, scaling support teams, and accelerating Omnipod Discover rollout.
Sampling workflow improvements ensure customers are supported and ready for long-term use.
Field incentives now emphasize durable starts and early customer success, with best practices shared across teams.
Customer service and clinical retention specialists provide targeted support during the first 90 days, proven effective in pilot programs.
Omnipod Discover, a digital health platform, will be fully launched by year-end to enhance engagement and retention.
Innovation pipeline and product development
Recent launches include a second-generation algorithm for tighter glycemic control and FreeStyle Libre 3 Plus integration.
Omnipod 6, launching in 2027, will offer a new algorithm, improved wear flexibility, and updatable pods for faster innovation.
Type 2 fully closed loop system, in pivotal study, targets a disruptively simple user experience and broader primary care adoption by 2028.
Continued algorithm updates and hardware innovations are planned through 2029 and beyond.
Latest events from Insulet
- Growth moderates as type 2 retention challenges are addressed and new innovations launch.PODD
Wells Fargo 21st Annual Healthcare Conference - Market-leading AID growth, innovation, and global expansion drive strong financial performance.PODD
Investor presentation - Q2 2026 revenue rose 23.5% to $801.7M, with Omnipod growth and margin expansion.PODD
Q2 2026 - Market-leading AID growth, innovation, and global expansion drive strong financial performance.PODD
Investor presentation - Innovation, global expansion, and strong growth drive leadership in diabetes management.PODD
46th Annual William Blair Growth Stock Conference - Innovation and clinical performance drive robust growth and margin expansion in diabetes care.PODD
Bank of America Global Healthcare Conference 2026 - Q3 2024 revenue up 25.7% to $543.9M; guidance raised on Omnipod 5 and FDA expansion.PODD
Q3 2024 - Q2 revenue up 23%, net income surged, and full-year guidance raised on Omnipod 5 growth.PODD
Q2 2024 - Q1 2025 revenue up 30% to $569M, gross margin 71.9%, 2025 guidance raised on Omnipod 5 growth.PODD
Q1 2025